SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Home
/
update
/
details

BePRECISE Consortium Releases Guidelines for Precision Medicine Research Reporting

NextEdge Admin

23 Jul 2024

3 min 17 sec

A consortium of experts in precision medicine, cardiometabolic diseases, and statistics, alongside patient advocates, has released new guidelines aimed at enhancing patient access to precision medicines worldwide. Published in Nature Medicine, these guidelines were developed by the BePRECISE consortium (Better Precision-data Reporting of Evidence from Clinical Intervention Studies & Epidemiology), which includes members from various income-level countries.

The guidelines emphasize transparency, accuracy, safety, and equity in precision medicine, establishing standards to better compare findings across different studies. Paul Franks, a professor at Lund University in Sweden and chair of the guidelines committee, highlighted the challenges posed by the heterogeneity of diseases and varied research methodologies in precision medicine. He emphasized the need for standardized reporting to facilitate comparison and implementation of research findings.

The guidelines include a 23-item checklist addressing key sections of scientific publications: title and abstract, background, methods, results, and discussion. Researchers are advised to specify if the study involves prevention, diagnostics, treatment, or prognostics, and to detail the population or subgroup analyzed. The methods section should explain the rationale for tracking certain outcomes, and define biomarkers, molecular markers, and clinical characteristics, as well as societal, economic, geographic, and cultural factors used for patient stratification or outcome prediction.

A significant focus of the guidelines is on health equity. Researchers are urged to consider under-represented and underserved groups in their studies and to discuss the impact of their inclusion or exclusion. The checklist includes a specific section on health equity to ensure inclusivity in precision medicine research.

Michèle Ramsay, director of the Sydney Brenner Institute for Molecular Bioscience at the University of the Witwatersrand in South Africa and consortium member, stressed the importance of including African ancestry in precision medicine research. She highlighted Africa's unique genetic diversity and challenging environments as valuable contributions to global precision medicine solutions. Ramsay noted that the BePRECISE checklist is crucial for generating and sharing research data, ensuring studies can be accurately compared, and avoiding a one-size-fits-all approach that may not suit African populations.